Materials and methods for viral engineering
By employing a multi-pseudotyped virus approach with envelope glycoproteins RD114 and VSV-G and Kolliphor treatment, the method addresses the challenges of low titer and transduction efficiency in retroviral vector production, achieving improved gene therapy outcomes in immune cells.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- JANSSEN BIOTECH INC
- Filing Date
- 2026-01-07
- Publication Date
- 2026-07-16
AI Technical Summary
Existing methods for producing retroviral vectors for gene therapy face challenges in achieving high titers and efficient transduction of target cells, particularly in immune cells like gamma delta T cells, limiting their effectiveness in gene therapy applications.
A method involving the use of mammalian cell lines treated with a composition containing packaging plasmids encoding multiple envelope glycoproteins, such as RD114 and VSV-G, and the addition of Kolliphor during incubation to enhance viral production and transduction efficiency, resulting in a multi-pseudotyped virus with significantly higher titers and improved transduction efficiency in immune cells.
The method produces a multi-pseudotyped virus with enhanced titer and transduction efficiency, enabling effective gene transfer and therapeutic applications, particularly in gamma delta T cells, by using a combination of envelope glycoproteins like RD114 and VSV-G.
Smart Images
Figure IMGF000013_0001 
Figure IMGF000067_0001_TABLE 
Figure IMGF000068_0001_TABLE